AUTHORS
Thura Win Htut, MD, FRCPath, Alex Bataller, MD, PhD2, Alexandre Bazinet, MD3, Courtney DiNardo, MD, MSCE4, Naval Daver, MD5, Gautham Borthakur6, Fadi G. Haddad, MD7, Jayastu Senapati, MBBS, MD, DM8, Nicholas Short, MD9, Elias Jabbour, MD10, Abhishek Maiti, MBBS11, Naveen Pemmaraju, MD12, Nitin Jain, MD13, Kelly Sharon Chien, MD14, Lucia Masarova, MD15, Caitlin R Rausch, PharmD, BCOP16, Yesid Alvarado17, Guillermo Montalban-Bravo, MD18, Ghayas C. Issa, MD19, Uday Popat, MD, MBA20, Elizabeth Shpall, MD21, Guillermo Garcia-Manero, MD22, Farhad Ravandi, MD23, Hagop Kantarjian, MD24, Tapan Kadia I, MD25
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
23 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
24 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
25 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background
Cladribine, low-dose cytarabine, and venetoclax (CLAD/LDAC/VEN) alternating with azacitidine and venetoclax (AZA/VEN) have shown high response rates and encouraging survival in older or intensive chemotherapy in-eligible patients (pts) with newly diagnosed acute myeloid leukemia (ND AML). We report an extended cohort with longer follow-up, evaluating long-term efficacy, durability of remission, measurable residual disease (MRD), and prognostic factors associated with outcomes.
Methods
Pts with ND AML treated on a phase II trial of CLAD/LDAC/VEN alternating with AZA/VEN (November 2018 to July 2026) were analyzed. Responses and MRD were assessed by AML response criteria and by flow cytometry. Overall survival (OS) and event-free survival (EFS) were estimated by Kaplan-Meier, cumulative incidence of relapse (CIR) and non-relapse mortality (NRM) by competing-risk methods, and prognostic factors by Cox regression. A 4-month landmark analysis evaluated the impact of allogenic stem cell transplantation (SCT) on OS.
Results
A total of 229 pts was included. Median age was 68 years (range, 39-84), including 26(11%) pts aged ≥ 75 yrs; 24% had secondary AML: 14%, 20% and 66% had ELN2022 favorable, intermediate and adverse risk disease, and 22% had complex cytogenetics. TP53, NPM1, and KRAS mutations were present in 23%, 17%, and 5%. Complete remission (CR) was achieved in 160 (72.4%), CR with incomplete hematologic recovery (CRi) in 26 (12%), The CR/CRi rate was 61% in a prespecified subgroup of pts with TP53 mutated AML vs. 91% in pts without TP53-mut AML (P<0.001). Median time to best response was 28 days (20-355). The median number of treatment cycles was 2 (1-18). Among 183 responding pts with evaluable MRD, 134 (73%) achieved MRD negativity. Median time to absolute neutrophil count recovery ≥1 x109/L and platelet recovery ≥100 x 109/L during cycle 1 was 27 (19-113) and 24 (18-54) days.
At a median follow-up of 40.8 months (m) (95%CI, 34-47.9), median OS overall was 49.7 m (95%CI, 28.2-72.6). Median EFS was 29.2 m (95%CI, 17.1-52.6). Survival differed significantly by ELN 2022 risk (P<0.001). Median OS was NR, 59.4, and 21 m, while median EFS was NR, 52.4, and 14.7 m in ELN 2022 favorable-, intermediate-, adverse-risk AML. Median OS and EFS among pts in the TP53-wildtype cohort was 59.4 and 52.4 m.
Among pts with evaluable post-CR MRD, MRD status strongly identified pts with durable response. Median OS was 81.3 m in MRD-negative vs 18.3 m in MRD-positive pts (HR, 3.37, 95% CI, 2.08-5.44; P<0.001), while median EFS was 72.6 vs 7 m, respectively (HR, 3.52; 95% CI, 2.24-5.53; p<0.001). At 12 and 24 months, among pts who achieved CR/CRi, CIR was 9.9% and 13.3% in MRD-negative vs 29.4% and 34.5% in MRD-positive pts, while NRM was 12.2% and 18.2% vs 27.2% and 27.2% (Gray’s P<0.001). Among 177 pts in the TP53-wildtype (WT) cohort, the 2-yr OS, EFS, and CIR were 68.1%, 62.4%, and 15.4%. Among SCT recipients with evaluable pre-SCT MRD, MRD positivity was associated with inferior EFS (HR, 2.39; P=0.023), but not OS (HR, 2.05; P=0.08).
On univariate analysis, TP53, KRAS mutation, and complex cytogenetics predicted inferior OS/EFS, whereas NPM1 and DDX41 mutations predicted favorable outcomes (all P<0.05). On multivariable analysis, non-complex cytogenetics (OS/EFS HR, 0.44/0.37) and NPM1 mutation (HR, 0.49/0.44) independently predicted favorable OS/EFS, whereas KRAS mutation predicted inferior OS/EFS (HR, 2.27/3.15; all P<0.05). Among pts with NPM1-mutation, CR/CRi was 97%, and landmark SCT was associated with 5 y OS/EFS (86.8% each vs 42.7%/43.3%).
A total of 112 pts (49%) underwent SCT. A 4-month landmark analysis restricted pts achieving CR/CRi who were alive and under follow-up at 4 months, median OS was NR in SCT and 35.1 m (95% CI,18-59.3) in non-SCT groups with 3-year OS was 72% in SCT vs 48% in non-SCT groups, and 5-year OS was 67.4 vs 30.5; (P<0.001), respectively. SCT was associated with significantly improved OS (HR, 0.43; 95% CI 0.27-0.68; P<0.001).
Conclusion
With long-term follow-up, CLAD/LDAC/VEN alternating with AZA/VEN continues to demonstrate durable responses and prolonged survival in ND AML. MRD negativity was strongly associated with superior OS and EFS and lower relapse incidence. Among pts with TP53-WT AML, the results were very encouraging with a long-term OS of 68.1%. Among CR/CRi responders reaching the 4-month landmark, SCT by 4 months was associated with significantly improved long-term survival.
DISCLOSURES
Thura Win Htut, MD, FRCPath: No relevant conflicts of interest to declare.